Selectivity Challenges in Docking Screens for GPCR Targets and Antitargets

To investigate large library docking’s ability to find molecules with joint activity against on-targets and selectivity versus antitargets, the dopamine D2 and serotonin 5-HT2A receptors were targeted, seeking selectivity against the histamine H1 receptor. In a second campaign, κ-opioid receptor ligands were sought with selectivity versus the μ-opioid receptor. While hit rates ranged from 40% to 63% against the on-targets, they were just as good against the antitargets, even though the molecules were selected for their putative lack of binding to the off-targets. Affinities, too, were often as good or better for the off-targets. Even though it was occasionally possible to find selective molecules, such as a mid-nanomolar D2/5-HT2A ligand with 21-fold selectivity versus the H1 receptor, this was the exception. Whereas false-negatives are tolerable in docking screens against on-targets, they are intolerable against antitargets; addressing this problem may demand new strategies in the field.

[1]  M. Spetea,et al.  Current κ opioid receptor ligands and discovery of a new molecular scaffold as a κ opioid receptor antagonist using pharmacophore-based virtual screening. , 2014, Current pharmaceutical design.

[2]  J. Irwin,et al.  Docking Screens for Novel Ligands Conferring New Biology. , 2016, Journal of medicinal chemistry.

[3]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[4]  P. Barth,et al.  Computational design of ligand binding membrane receptors with high selectivity , 2017, Nature chemical biology.

[5]  Ali Jazayeri,et al.  Crystal structure of the GLP-1 receptor bound to a peptide agonist , 2017, Nature.

[6]  Paul Ernsberger,et al.  H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs , 2003, Neuropsychopharmacology.

[7]  Richard D. Taylor,et al.  Combining Molecular Scaffolds from FDA Approved Drugs: Application to Drug Discovery. , 2017, Journal of medicinal chemistry.

[8]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[9]  J. Andrew McCammon,et al.  Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor , 2016, Proceedings of the National Academy of Sciences.

[10]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[11]  Davide Provasi,et al.  Exploring molecular mechanisms of ligand recognition by opioid receptors with metadynamics. , 2009, Biochemistry.

[12]  Jing Liu,et al.  In silico design of novel probes for the atypical opioid receptor MRGPRX2 , 2016, Nature chemical biology.

[13]  Martin Zacharias,et al.  Monte Carlo replica‐exchange based ensemble docking of protein conformations , 2017, Proteins.

[14]  Gianni De Fabritiis,et al.  Molecular-Simulation-Driven Fragment Screening for the Discovery of New CXCL12 Inhibitors , 2018, J. Chem. Inf. Model..

[15]  Hitomi Oki,et al.  Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity , 2010, Journal of Pharmacology and Experimental Therapeutics.

[16]  Maria F. Sassano,et al.  Automated design of ligands to polypharmacological profiles , 2012, Nature.

[17]  Ruben Abagyan,et al.  Structure of the human histamine H1 receptor complex with doxepin , 2011, Nature.

[18]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[19]  Maria F. Sassano,et al.  Colloidal Aggregation Causes Inhibition of G Protein-Coupled Receptors , 2013, Journal of medicinal chemistry.

[20]  P. Hajduk,et al.  Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks. , 2010, Current opinion in chemical biology.

[21]  Quanjie Li,et al.  Progress in the Rational Design for Polypharmacology Drug. , 2016, Current pharmaceutical design.

[22]  Maria F. Sassano,et al.  A Pharmacological Organization of G Protein-coupled Receptors , 2012, Nature Methods.

[23]  G. Bottegoni,et al.  Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727 , 2018, Nature.

[24]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[25]  James G. Nourse,et al.  Reoptimization of MDL Keys for Use in Drug Discovery , 2002, J. Chem. Inf. Comput. Sci..

[26]  T. Klabunde,et al.  Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.

[27]  Xin Chen,et al.  Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65 , 2015, Nature.

[28]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[29]  Christian Kramer,et al.  Improving Docking Results via Reranking of Ensembles of Ligand Poses in Multiple X-ray Protein Conformations with MM-GBSA , 2014, J. Chem. Inf. Model..

[30]  M. Ehlers,et al.  Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor , 2018, Nature Communications.

[31]  Gerhard Klebe,et al.  Ligand-supported homology modeling of g-protein-coupled receptor sites: models sufficient for successful virtual screening. , 2004, Angewandte Chemie.

[32]  S. Frantz.  Drug discovery: Playing dirty , 2005, Nature.

[33]  Maria F. Sassano,et al.  Discovery of β-Arrestin–Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy , 2011, Proceedings of the National Academy of Sciences.

[34]  S. Grzesiek,et al.  Backbone NMR reveals allosteric signal transduction networks in the β1-adrenergic receptor , 2016, Nature.

[35]  B. Kobilka,et al.  The role of protein dynamics in GPCR function: insights from the β2AR and rhodopsin. , 2014, Current opinion in cell biology.

[36]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[37]  Raphael Nudelman,et al.  An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. , 2006, Journal of medicinal chemistry.

[38]  Thierry Langer,et al.  Common Hits Approach: Combining Pharmacophore Modeling and Molecular Dynamics Simulations , 2017, J. Chem. Inf. Model..

[39]  Stefano Alcaro,et al.  A Pipeline To Enhance Ligand Virtual Screening: Integrating Molecular Dynamics and Fingerprints for Ligand and Proteins , 2015, J. Chem. Inf. Model..

[40]  N. Grishin,et al.  PROMALS3D: a tool for multiple protein sequence and structure alignments , 2008, Nucleic acids research.

[41]  Peter Kolb,et al.  Structure‐Based Virtual Screening for Dopamine D2 Receptor Ligands as Potential Antipsychotics , 2016, ChemMedChem.

[42]  Brian K. Shoichet,et al.  Rapid Context-Dependent Ligand Desolvation in Molecular Docking , 2010, J. Chem. Inf. Model..

[43]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[44]  R. Stevens,et al.  Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.

[45]  S. Snyder,et al.  Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase , 2007, Proceedings of the National Academy of Sciences.

[46]  Brian K. Shoichet,et al.  The incorporation of protein flexibility and conformational energy penalties in docking screens to improve ligand discovery , 2014, Nature chemistry.

[47]  Anat Levit,et al.  STRUCTURE OF THE D2 DOPAMINE RECEPTOR BOUND TO THE ATYPICAL ANTIPSYCHOTIC DRUG RISPERIDONE , 2018, Nature.

[48]  Mark C. Fishman,et al.  Pharmaceuticals: A new grammar for drug discovery , 2005, Nature.

[49]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[50]  Claudio N. Cavasotto,et al.  Open challenges in structure-based virtual screening: Receptor modeling, target flexibility consideration and active site water molecules description. , 2015, Archives of biochemistry and biophysics.

[51]  R. Stevens,et al.  Structural Features for Functional Selectivity at Serotonin Receptors , 2013, Science.

[52]  David E. Gloriam,et al.  5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology , 2018, Cell.

[53]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[54]  Kenneth Jones,et al.  Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.

[55]  Liaoyuan A. Hu,et al.  Structural Basis for Apelin Control of the Human Apelin Receptor. , 2017, Structure.

[56]  Kevan M. Shokat,et al.  Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.

[57]  Jean-Louis Reymond,et al.  Fragment Database FDB-17 , 2017, J. Chem. Inf. Model..

[58]  Peter Kolb,et al.  Identifying modulators of CXC receptors 3 and 4 with tailored selectivity using multi-target docking. , 2015, ACS chemical biology.

[59]  Jonathan A. Javitch,et al.  Discovery of a Novel Selective Kappa-Opioid Receptor Agonist Using Crystal Structure-Based Virtual Screening , 2013, J. Chem. Inf. Model..

[60]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[61]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[62]  Qingyi Yang,et al.  Building alternate protein structures using the elastic network model , 2009, Proteins.

[63]  M. Congreve,et al.  Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs. , 2017, Trends in pharmacological sciences.

[64]  Hualiang Jiang,et al.  Structure of the glucagon receptor in complex with a glucagon analogue , 2018, Nature.

[65]  Henry Lin,et al.  Structure-based discovery of opioid analgesics with reduced side effects , 2016, Nature.

[66]  Anat Levit,et al.  D4 dopamine receptor high-resolution structures enable the discovery of selective agonists , 2017, Science.

[67]  Avner Schlessinger,et al.  Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.

[68]  Michael M. Mysinger,et al.  Structure-based ligand discovery for the protein–protein interface of chemokine receptor CXCR4 , 2012, Proceedings of the National Academy of Sciences.

[69]  B. Shoichet,et al.  Hierarchical docking of databases of multiple ligand conformations. , 2005, Current topics in medicinal chemistry.

[70]  Florent Chevillard,et al.  SCUBIDOO: A Large yet Screenable and Easily Searchable Database of Computationally Created Chemical Compounds Optimized toward High Likelihood of Synthetic Tractability , 2015, J. Chem. Inf. Model..

[71]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2016, Current protocols in protein science.

[72]  Peter Kolb,et al.  Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.

[73]  Matteo Masetti,et al.  Fully Flexible Docking via Reaction-Coordinate-Independent Molecular Dynamics Simulations , 2018, J. Chem. Inf. Model..

[74]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[75]  David Rodríguez,et al.  Discovery of GPCR Ligands by Molecular Docking Screening: Novel Opportunities Provided by Crystal Structures. , 2015, Current topics in medicinal chemistry.

[76]  J. Bajorath,et al.  Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.

[77]  Dahlia R. Weiss,et al.  Structure-based discovery of selective positive allosteric modulators of antagonists for the M2 muscarinic acetylcholine receptor , 2018, Proceedings of the National Academy of Sciences.

[78]  Woody Sherman,et al.  Large-Scale Systematic Analysis of 2D Fingerprint Methods and Parameters to Improve Virtual Screening Enrichments , 2010, J. Chem. Inf. Model..

[79]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using Modeller , 2006, Current protocols in bioinformatics.

[80]  Albert C. Pan,et al.  The Dynamic Process of β2-Adrenergic Receptor Activation , 2013, Cell.